Danaher Upgraded Amid Positive Earnings Outlook and Acquisition Interest
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 Jan 26
Source: seekingalpha
Danaher Corporation (DHR) shares rose 3.01% as the stock reached a 20-day high, reflecting strong market performance.
TD Cowen upgraded Danaher’s price target from $260 to $270 while maintaining a Buy rating, citing optimism for the life sciences tools sector. Additionally, at the J.P. Morgan Healthcare Conference, Danaher projected its adjusted diluted EPS for 2025 to be between $7.70 and $7.80, indicating strong profitability. The company also anticipates mid-single-digit percentage growth in sales for the fourth quarter, demonstrating sustained demand in its sectors.
This positive outlook, combined with acquisition interest in Qiagen, positions Danaher favorably in the market, reinforcing investor confidence in its growth potential.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 261.57 USD with a low forecast of 235.00 USD and a high forecast of 310.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 224.540
Low
235.00
Averages
261.57
High
310.00
Current: 224.540
Low
235.00
Averages
261.57
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
